Belotero – An innovative hyaluronic acid dermal filler range by Merz Aesthetics
Merz Aesthetics, a division of Merz Pharmaceuticals and global leader in the field of aesthetics, proudly introduces Belotero®: its range of innovative hyaluronic acid fillers, provided with and without lidocaine.
The Belotero® range up until now was comprised of three hyaluronic acid fillers: Soft, Basic, and Intense. In 2011, Belotero® Balance (known as Belotero® Basic) was successfully launched in the US. With the acquisition of the Swiss company Anteis in November 2013, Merz is now proud to extend the Belotero® range. Belotero® Hydro, Belotero® Soft, Belotero® Balance, Belotero® Intense and Belotero® Volume deliver optimal results for deep skin rehydration, the smoothing and filling of wrinkles or the restoring of facial volume. For additional comfort and convenience the Belotero® fillers are now also available with lidocaine.
- Belotero® Hydro: Belotero® Hydro is an entry-level product that combines non-crosslinked HA with Glycerol and is designed for targeted rehydration whilst restoring radiance and elasticity.
- Belotero® Soft: Belotero® Soft ensures the optimal correction and smoothening of fine lines due to its excellent cohesivity.
- Belotero® Balance: Belotero® Balance integrates seamless into the skin and is designed for the correction of moderate lines and wrinkles
- Belotero® Intense: Belotero® Intense fills deep lines and is optimal for lip augmentation treatments due to a balanced elasticity that safely provides excellent skin support
- Belotero® Volume: Belotero® Volume models and restores facial volumes through its outstanding malleability and powerful volumising capacity.
Belotero® Soft, Balance and Intense will be available in key markets as of April 2014. Belotero® Hydro and Volume will be launched at a later timepoint in 2014. The entire Belotero® range will become available worldwide.
Hyaluronic acid – the natural moisturizer of the skin
The signs and symptoms of the natural ageing process can be reduced by replacing the lost hyaluronic acid. The secret to Belotero®’s success story is its patented Dynamic Cross-Linking Technology. This innovative technology allows predictable and particularly harmonious results by tailoring an approach that optimizes the balance of the parameters cohesivity, elasticity and plasticity specifically addressing the needs of the targeted skin layer. Due to this technology, Belotero® Soft and Balance® can be administered very superficially using the Blanching Technique. Since its introduction in 2005, Belotero® has successfully established itself as a brand of excellence amongst physicians. It is known for its high safety profile, great performance and high customer and patient satisfaction.
With this now complete product portfolio, Merz Aesthetics further strengthens its position as one of the leading manufacturers of state of the art HA dermal fillers worldwide.
For further information, please visit: www.merzaesthetics.com.
About the Merz Pharma Group
Merz is a privately held pharmaceutical company based in Frankfurt, Germany. The company is active in research, development and distribution of innovative products in the areas of aesthetic medicine and dermatology as well as in the field of neurologically induced movement disorders.
For the treatment of neurologically induced movement disorders, Merz developed Xeomin®, the first botulinum toxin that is free of complex proteins. Another core competency of Merz lies in medical and aesthetic dermatology. Merz Aesthetics offers a tailored and harmonized portfolio of products for minimally invasive treatments. With the fillers Radiesse®, Belotero®, Glytone® and the neurotoxin Bocouture®/Xeomin®, the company is an important player in the aesthetics market.
In the consumer products segment, Merz Consumer Care is the leading provider of OTC medication, dietary supplements and skincare products in the German-speaking countries with its well-known tetesept® and Merz Spezial® brands. The Merz Pharma Group employs 2,443 people worldwide (prior year: 2,396). The Company generated revenue of EUR 980.2 million in fiscal year 2012/13 (prior year: EUR 913.1 million).
Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstraße 100